You are here

Millennium: The Takeda Oncology Company Receives CEO Cancer Gold Standard™ accreditation

April 23, 2009

CARY, NC (April 23, 2009) – Millennium: The Takeda Oncology Company was accredited with the CEO Cancer Gold Standard certification, recognizing the company’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.


William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, in collaboration with the National Cancer Institute, many of its designated cancer centers, the American Cancer Society, CDC and leading health professionals.


“Adopting the Gold Standard is a tribute to Millennium’s standing as a global oncology leader and their commitment to helping us win the battle against cancer, beginning with their own employees and family members” said Weldon.   


The CEO Cancer Gold Standard, calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.


The most recent President's Cancer Panel report, “Maximizing our Nation’s Investment in Cancer: Three Crucial Actions for America’s Health”, identified the CEO Cancer Gold Standard as an initiative that emphasizes cancer screening, tobacco control, cancer education, lifestyle modification, and access to cancer treatment when needed.


Other organizations championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.


About Millenium

Millennium: The Takeda Oncology Company combines the innovative science of a leading American biopharmaceutical company with the global assets of Japan’s largest pharmaceutical company. As the part of the Takeda family, Millennium is a global center of excellence in oncology with a robust pipeline, focusing on disease pathways for a variety of cancers. Additional information about Millennium is available through its website.


About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standardencouraging its widespread adoption in workplaces across the country.  For more information on the CEO Cancer Gold Standard™ and the accreditation process, please visit